Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemlapodect in Tourette Syndrome
NCT06315751Phase 2Active, not recruiting
- Sponsor
- Noema Pharma
- Start
- Sep 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of gemlapodect in Tourette syndrome (TS), sponsored by Noema Pharma. Started Sep 2024; status: active, not recruiting.
02
Drugs
gemlapodect
03
Conditions
Tourette syndrome (TS)
Beyond the preview
Go deeper on NCT06315751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06315751.